Barbara Binzak Blumenfeld and Matthew Fedowitz presented a webinar in partnership with Informa Pharma Intelligence entitled "Leveraging Your Pharmaceutical Product Portfolio: Driving M&A And Target Identification Through Research-Driven Strategies."
Whether your company has a brand name drug that is facing impending expiration of patent or market exclusivity, you represent a generic drug company looking to introduce or acquire a product, or you are an investor looking to drive the value of a deal based on a company’s drug product offerings, you need to be able to evaluate a pharmaceutical product portfolio against the broader drug industry landscape, anticipate potential roadblocks, and strategically determine growth areas and next steps.
Key takeaways included:
- Gaining insight into the value of a comprehensive IP/FDA regulatory pharmaceutical product analysis for driving strategic portfolio growth.
- Understanding how and why IP and FDA regulatory factors can be a driver of the value of a pharmaceutical product portfolio or deal.
- Learning how to assess, identify, and capitalize on gaps in your current product portfolio.